SMAD3 and ovarian cancer: In particular, it has been documented that GULP1 activates SMAD3 [27] or inactivates AKT/PDK1 and MAPK [28] in ovarian cancer cells, while it inhibits the nuclear translocation of NRF2 and subsequently reduces the expression of HMOX1 in bladder cancer cells [29].